WILMINGTON – A business unit of Wilmington-based global contract research organization, Pharmaceutical Product Development (PPD), is expanding its global footprint.
Accelerated Enrollment Solutions (AES) has acquired the clinical research site business of Bioclinica, expanding its reach into China, Latin America and Western Europe.
The transaction includes research sites from the merger of Bioclinica and CCBR-SYNARC in 2014.
The Pennsylvania-based research entity is also expanding its therapeutic area scope within the United States, adding four dedicated research sites in Florida, branded Compass Research.
AES now spans across five continents and 20 countries, with more than 180 research sites.
It offers pharmaceutical sponsors and contract research organizations site and enrollment solutions through its service brands Acurian, Optimal and Synexus, as well as in combination with PPD’s global clinical development services. AES is underwriting the dementia study.
“With these new assets operating on five continents, AES is a place where customers can receive 50-100% of their entire trial enrollment from one accountable solution, delivered by research locations that operate uniformly across the globe,” Roger Smith, senior vice president and general manager of AES, said in a statement.
PPD group launches major dementia study, to include 30,000 people
